The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1513
January 30, 2017
View Complete Issue         Table of Contents 2019 
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
January 30, 2017 (Issue: 1513)
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
Article code: 1513b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.